Article
Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Melanoma research - 1 Oct 2013
Guerreschi Pierre, Scalbert Camille, Qassemyar Ahmad, Kluza Jerome, Ravasi Laura, Huglo Damien, Martinot-Duquennoy Veronique, Formstecher Pierre, Marchetti Philippe, Mortier Laurent
Abstract excerpt
Recently, the BRAF V600 inhibitor, vemurafenib, has revolutionized the therapeutic management of metastatic melanoma. However, adverse effects and the onset of resistance are frequently observed, limiting the efficacy of this treatment. Patient-derived tumor xenografts (PDTX) engrafted in immunocompromised mice have been proposed as valuable preclinical models that can predict clinical response to treatments....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.